vs

Side-by-side financial comparison of ACCESS Newswire Inc. (ACCS) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $5.8M, roughly 1.9× ACCESS Newswire Inc.). ACCESS Newswire Inc. runs the higher net margin — -9.9% vs -186.0%, a 176.0% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -0.5%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 2.0%).

PR Newswire is a distributor of press releases headquartered in Chicago. The service was created in 1954 to allow companies to electronically send press releases to news organizations, using teleprinters at first. The founder, Herbert Muschel, operated the service from his house in Manhattan for approximately 15 years. The business was eventually sold to Western Union and then United Newspapers of London. In December 2015, Cision Inc. announced it would acquire the company. On January 1, 2021...

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

ACCS vs CCCC — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.9× larger
CCCC
$11.0M
$5.8M
ACCS
Growing faster (revenue YoY)
CCCC
CCCC
+113.3% gap
CCCC
112.8%
-0.5%
ACCS
Higher net margin
ACCS
ACCS
176.0% more per $
ACCS
-9.9%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
2.0%
ACCS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACCS
ACCS
CCCC
CCCC
Revenue
$5.8M
$11.0M
Net Profit
$-576.0K
$-20.5M
Gross Margin
77.4%
Operating Margin
-13.1%
-210.1%
Net Margin
-9.9%
-186.0%
Revenue YoY
-0.5%
112.8%
Net Profit YoY
94.4%
40.7%
EPS (diluted)
$-0.16
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACCS
ACCS
CCCC
CCCC
Q4 25
$5.8M
$11.0M
Q3 25
$5.7M
$11.2M
Q2 25
$5.6M
$6.5M
Q1 25
$5.5M
$7.2M
Q4 24
$5.8M
$5.2M
Q3 24
$5.6M
$15.4M
Q2 24
$6.0M
$12.0M
Q1 24
$5.6M
$3.0M
Net Profit
ACCS
ACCS
CCCC
CCCC
Q4 25
$-576.0K
$-20.5M
Q3 25
$-45.0K
$-32.2M
Q2 25
$-475.0K
$-26.0M
Q1 25
$5.4M
$-26.3M
Q4 24
$-10.2M
$-34.6M
Q3 24
$-466.0K
$-24.7M
Q2 24
$7.0K
$-17.7M
Q1 24
$-139.0K
$-28.4M
Gross Margin
ACCS
ACCS
CCCC
CCCC
Q4 25
77.4%
Q3 25
74.6%
Q2 25
76.2%
Q1 25
78.0%
Q4 24
75.2%
Q3 24
75.0%
Q2 24
77.2%
Q1 24
75.1%
Operating Margin
ACCS
ACCS
CCCC
CCCC
Q4 25
-13.1%
-210.1%
Q3 25
-3.2%
-306.4%
Q2 25
-4.4%
-441.0%
Q1 25
-12.4%
-402.9%
Q4 24
-245.8%
-728.4%
Q3 24
-10.7%
-183.9%
Q2 24
-8.8%
-178.6%
Q1 24
-15.5%
-1060.2%
Net Margin
ACCS
ACCS
CCCC
CCCC
Q4 25
-9.9%
-186.0%
Q3 25
-0.8%
-286.4%
Q2 25
-8.5%
-402.6%
Q1 25
98.4%
-363.7%
Q4 24
-175.0%
-667.8%
Q3 24
-8.3%
-160.6%
Q2 24
0.1%
-147.6%
Q1 24
-2.5%
-933.2%
EPS (diluted)
ACCS
ACCS
CCCC
CCCC
Q4 25
$-0.16
$-0.09
Q3 25
$-0.01
$-0.44
Q2 25
$-0.12
$-0.37
Q1 25
$1.40
$-0.37
Q4 24
$-2.66
$-0.50
Q3 24
$-0.12
$-0.35
Q2 24
$0.00
$-0.26
Q1 24
$-0.04
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACCS
ACCS
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$3.0M
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$30.3M
$256.6M
Total Assets
$42.0M
$359.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACCS
ACCS
CCCC
CCCC
Q4 25
$3.0M
$74.6M
Q3 25
$3.3M
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$4.1M
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Stockholders' Equity
ACCS
ACCS
CCCC
CCCC
Q4 25
$30.3M
$256.6M
Q3 25
$30.8M
$154.4M
Q2 25
$30.7M
$174.1M
Q1 25
$30.9M
$195.1M
Q4 24
$25.2M
$216.0M
Q3 24
$35.3M
$242.7M
Q2 24
$35.4M
$247.1M
Q1 24
$35.2M
$258.3M
Total Assets
ACCS
ACCS
CCCC
CCCC
Q4 25
$42.0M
$359.1M
Q3 25
$44.0M
$265.5M
Q2 25
$45.6M
$296.5M
Q1 25
$47.3M
$319.5M
Q4 24
$50.6M
$349.6M
Q3 24
$61.7M
$376.1M
Q2 24
$62.8M
$381.1M
Q1 24
$64.4M
$398.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACCS
ACCS
CCCC
CCCC
Operating Cash FlowLast quarter
$258.0K
$-22.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACCS
ACCS
CCCC
CCCC
Q4 25
$258.0K
$-22.1M
Q3 25
$-582.0K
$-31.2M
Q2 25
$135.0K
$-12.1M
Q1 25
$747.0K
$-33.3M
Q4 24
$866.0K
$-17.9M
Q3 24
$1.5M
$-24.1M
Q2 24
$-190.0K
$-5.0M
Q1 24
$986.0K
$-18.1M
Free Cash Flow
ACCS
ACCS
CCCC
CCCC
Q4 25
Q3 25
$-590.0K
$-31.6M
Q2 25
Q1 25
$735.0K
Q4 24
$-17.9M
Q3 24
$1.5M
$-24.1M
Q2 24
$-5.2M
Q1 24
$970.0K
FCF Margin
ACCS
ACCS
CCCC
CCCC
Q4 25
Q3 25
-10.3%
-281.5%
Q2 25
Q1 25
13.4%
Q4 24
-346.5%
Q3 24
26.5%
-157.2%
Q2 24
-43.1%
Q1 24
17.4%
Capex Intensity
ACCS
ACCS
CCCC
CCCC
Q4 25
0.0%
Q3 25
0.1%
3.7%
Q2 25
0.0%
Q1 25
0.2%
Q4 24
0.0%
0.1%
Q3 24
0.1%
0.1%
Q2 24
0.0%
1.6%
Q1 24
0.3%
0.0%
Cash Conversion
ACCS
ACCS
CCCC
CCCC
Q4 25
Q3 25
Q2 25
Q1 25
0.14×
Q4 24
Q3 24
Q2 24
-27.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACCS
ACCS

Cost To Deliver Products$3.1M54%
Employee Costs$1.7M29%
Other$1.0M17%

CCCC
CCCC

Segment breakdown not available.

Related Comparisons